Despite being mixed, Fresenius’ Q1 report looks a bit uninspiring, which is not bad as the world creaks under the weight of the virus. But not very things is running perfectly. Kabi’s issues seem to have worsened, which legitimises the CEO change ex-post. Unfortunately, management was not too good at providing many details about the cost-cutting programme.
Figures were a notch above our expectations and slightly above street expectations (top line: +1%; adjusted EBITDA: +2%).
06 May 2021
A non-event and that’s good
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A non-event and that’s good
Despite being mixed, Fresenius’ Q1 report looks a bit uninspiring, which is not bad as the world creaks under the weight of the virus. But not very things is running perfectly. Kabi’s issues seem to have worsened, which legitimises the CEO change ex-post. Unfortunately, management was not too good at providing many details about the cost-cutting programme.
Figures were a notch above our expectations and slightly above street expectations (top line: +1%; adjusted EBITDA: +2%).